The escalating research concentration on fibrotic disorders and their extensive medical ramifications has positioned CTGF inhibitors as central elements in therapeutic development and investment ventures. CTGF, serving as a matricellular protein scientifically termed CCN2, performs critical roles in tissue transformation, fibrotic evolution, and wound healing systems. Excessive expression of...